I-1-deficiency negatively impacts survival in a cardiomyopathy mouse model

AIMS: Hypertrophic cardiomyopathy (HCM) is characterized by left ventricular hypertrophy, diastolic dysfunction and increased interstitial fibrosis. Current treatment is based on beta-adrenoceptor (AR) and calcium channel blockers. Since mice deficient of protein phosphatase-1 inhibitor-1 (I-1), an...

Descripción completa

Detalles Bibliográficos
Autores principales: Friedrich, Felix W., Sotoud, Hannieh, Geertz, Birgit, Weber, Silvio, Flenner, Frederik, Reischmann, Silke, Eschenhagen, Thomas, Carrier, Lucie, El-Armouche, Ali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5497269/
https://www.ncbi.nlm.nih.gov/pubmed/28785686
http://dx.doi.org/10.1016/j.ijcha.2015.05.010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5497269/
https://www.ncbi.nlm.nih.gov/pubmed/28785686
http://dx.doi.org/10.1016/j.ijcha.2015.05.010

Ejemplares similares